Perrigo Company plc
PRGO
Positions held
Your positionsPRGO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Perrigo's low forward P/E ratio of 5.84 suggests it may be undervalued compared to peers in the drug manufacturing industry, potentially attracting value-focused investors.
- Revenue increased by 6% compared to the prior quarter, reaching $1.0 billion.
- The current ratio stands at 2.32, indicating strong liquidity and the ability to cover short-term obligations.
- The company has faced significant challenges, with a negative profit margin of -41.85%, raising concerns about its profitability.
- Net income for the most recent quarter was a loss of $398.6 million, reflecting ongoing financial difficulties.
- Revenue growth has been negative at -3.2% year-over-year, indicating potential struggles in maintaining sales momentum.
Fundamentals
| Market cap | $2.01B | Enterprise value | $5.09B | Trailing P/E | — | Forward P/E | 6.05 |
| PEG | 1.14 | Price / book | 0.80 | Beta | 0.69 | Dividend yield | 8.00% |
| Revenue growth | -3.2% | Earnings growth | — | Gross margin | 33.3% | Operating margin | 3.8% |
| Profit margin | -41.9% | ROE | -48.7% | ROA | 2.0% | Debt / equity | 1.38 |
| Current ratio | 2.32 | Free cash flow | $437.21M | Analyst recommendation | none | Mean target | $16.50 |
| 52w high | $22.02 | 52w low | $9.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | $969M | $1.1B | $1.0B | $1.1B | — |
| Op margin | 3.8% | 3.5% | 7.6% | 9.0% | 5.3% | — |
| Net income | $74.5M | -$399M | -$1.4B | $7.5M | -$8.4M | — |
| Gross margin | 30.7% | 33.6% | 32.6% | 36.1% | 34.4% | — |
| Gross profit | $314M | $326M | $362M | $377M | $363M | — |
| Operating income | $39.0M | $33.6M | $84.4M | $93.4M | $55.6M | — |
- Revenue +6% vs prior quarter ($1.0B vs $969M).
- Gross margin 30.7% (was 33.6% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.4B | $4.7B | $4.5B | — |
| Op margin | 7.4% | 7.1% | 6.1% | 2.7% | — |
| Net income | -$1.4B | -$172M | -$12.7M | -$141M | — |
| Gross margin | 35.1% | 35.3% | 36.1% | 32.7% | — |
| Gross profit | $1.5B | $1.5B | $1.7B | $1.5B | — |
| Operating income | $313M | $312M | $284M | $121M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?
2026-09-04 · Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
2026-08-27 · Perrigo to Attend the Barclays Global Consumer Conference
2026-08-26 · PRGO or NEOG: Which Is the Better Value Stock Right Now?
2026-08-26 · Should Value Investors Buy Perrigo (PRGO) Stock?
2026-08-22 · This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.
2026-08-12 · Perrigo (PRGO) Q2 2026 Earnings Call Transcript
2026-08-10 · PRGO vs. NEOG: Which Stock Is the Better Value Option?
2026-08-10 · Are Investors Undervaluing Perrigo (PRGO) Right Now?
2026-08-09 · Perrigo (PRGO) Stock Trades At A Discount After A 62% Fall
2026-08-09 · Perrigo Q2 Earnings Call Highlights
2026-08-08 · Perrigo (PRGO) In Focus As Q2 Earnings Beat Revives The Undervalued Narrative
Price (daily)
Full chart · RSI · MACD · patterns